In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Apogee Therapeutics Inc (NASDAQ: APGE) was $55.85 for the day, up 6.65% from the previous closing price of $52.37. In other words, the price has increased by $6.65 from its previous closing price. On the day, 0.96 million shares were traded. APGE stock price reached its highest trading level at $56.215 during the session, while it also had its lowest trading level at $52.865.
Ratios:
Our analysis of APGE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 16.36 and its Current Ratio is at 16.36. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on September 25, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On July 07, 2025, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $100 to $115.
On March 13, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $95.Citigroup initiated its Buy rating on March 13, 2025, with a $95 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 01 ’25 when Dambkowski Carl sold 5,110 shares for $39.80 per share. The transaction valued at 203,378 led to the insider holds 284,733 shares of the business.
Dambkowski Carl sold 2,725 shares of APGE for $103,198 on Sep 03 ’25. The Chief Medical Officer now owns 233,548 shares after completing the transaction at $37.87 per share. On Aug 06 ’25, another insider, Dambkowski Carl, who serves as the Chief Medical Officer of the company, sold 2,725 shares for $37.78 each. As a result, the insider received 102,950 and left with 236,273 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APGE now has a Market Capitalization of 3777983744 and an Enterprise Value of 2776531712.
Stock Price History:
The Beta on a monthly basis for APGE is 1.25, which has changed by -0.06864661 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, APGE has reached a high of $63.50, while it has fallen to a 52-week low of $26.20. The 50-Day Moving Average of the stock is 41.71%, while the 200-Day Moving Average is calculated to be 43.73%.
Shares Statistics:
APGE traded an average of 648.18K shares per day over the past three months and 1103810 shares per day over the past ten days. A total of 46.10M shares are outstanding, with a floating share count of 39.57M. Insiders hold about 33.60% of the company’s shares, while institutions hold 83.20% stake in the company. Shares short for APGE as of 1759190400 were 9448327 with a Short Ratio of 14.58, compared to 1756425600 on 9201255. Therefore, it implies a Short% of Shares Outstanding of 9448327 and a Short% of Float of 32.959998.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate. The current performance of Apogee Therapeutics Inc (APGE) in the stock market.The consensus estimate for the next quarter is -$1.44, with high estimates of -$1.22 and low estimates of -$1.7.
Analysts are recommending an EPS of between -$3.51 and -$4.93 for the fiscal current year, implying an average EPS of -$4.45. EPS for the following year is -$5.25, with 5.0 analysts recommending between -$3.85 and -$6.28.
